Australian scientists hope to produce up to 100 million doses of a COVID-19 vaccine by the end of next year as Queensland researchers sign a major partnership with pharmaceutical giant CSL.
- The deal is being hailed as a major step forward in the race for a COVID-19 vaccine
- Human trials of the UQ vaccine candidate are due to begin in July
- CSL and a global alliance of researchers will fund the trials
A deal between the University of Queensland (UQ), CSL and the Coalition for Epidemic Preparedness Innovations (CEPI) comes after promising early results in the laboratory and aims to fast-track the development of a home-grown vaccine.
Under the deal, CSL and CEPI will fund human trials of the UQ-developed vaccine candidate.
The trials will start next month.
The vaccine is distinct from other candidates under development because it uses what is known as a “molecular clamp” — a technology patented by the university.
It involves the use of a “backbone” in the vaccine, which can be rapidly adapted for use against different pathogens by inserting new genetic or protein sequences.
It is designed to stimulate an immune response and protect against people developing COVID-19.
In the human trials, a boosting agent will be added with the aim of increasing the vaccine’s effectiveness.
A number of other candidate COVID-19 vaccines are in the pipeline, with several already being trialled in humans.
So far, only one vaccine, developed by Chinese scientists, has delivered promising findings in human trials which have been published in a medical journal.
Other companies working on vaccines have released patient results which have not been peer-reviewed.